×

Message

fsockopen(): unable to connect to ssl://query.yahooapis.com:443 (php_network_getaddresses: getaddrinfo failed: Name or service not known)

 

 

 

 

 

On April 7, 35 new technologies in innovative fields were exposed. Among these technologies: 3D, multi-layered reality, user interfaces for technical applications, entertainment, robotics, machine learning, etc.

Developers: Israeli start ups, academic institutions and Microsoft laboratories

 

Microsoft's R&D Center in Israel opened its yearly Think Next innovation event at Hangar 11 in the Tel Aviv port, on April 7. This event is taking place this year for the 6th time. About 1,800 participants are invited from the hi-tech industry, including: developers, development managers, chief technologists, entrepreneurs and start up companies, venture capital funds, students and researchers from academic institutions, and more.

 

The event, which takes place in cooperation with Microsoft Ventures, deals with 'unlimited innovation in technology' and shows the special capabilities of the Israeli industry to continue breaking limits by means of creativity. Although Microsoft promotes the Think Next events, it provides a central stage for young Israeli entrepreneurs to expose their innovative ideas and products to Microsoft's international senior staff, and to the leaders of Israeli hi tech. The Israeli entrepreneurs and their developments are also exposed to delegations from abroad, among them, a delegation of 50 managers of accelerator start ups from the whole world, who have arrived to the event and examine the Israeli innovations.

 

In the event, 35 new technologies are exposed: about half of them belong to Israeli start up companies and academic institutions, selected as part of Microsoft Ventures' activities within these companies and institutions. The second part presents technologies developed by Microsoft's R&D centers in Israel and throughout the world.

 

 

 

 

Yoram Yaacobi, Chairman of Microsoft's R&D centers in Israel, said: "The Israeli industry shows in this event innovations in a number of hottest technological fields in the world; among them: 3D, multi-layered reality, user interfaces for technical applications, entertainment, robotics, machine learning, etc. These developments strengthen the user capabilities and enrich our lives by means of friendly devices that will soon be available to all. For example, new devices will enable everyone to develop an application without any knowledge in programming. Everyone will be able to easily design a 3D object and print it. I hope that the exposure of start ups to delegations from abroad and to Israeli industry leaders will pave their way to success in the world market".

 

The guest of honor this year is Harry Shum, senior vice-president, manager of Microsoft's R&D and technology in the world, who came in his first visit to Israel. Harry Shum appeared in the conference in a free talk with Dr. Kira Radinsky, former researcher in Microsoft's research laboratory, researcher in the Technion, founder of Sales Predict, and one of the leading entrepreneurs in Israel.

 

Harry Shum is responsible of Microsoft's technological strategy and on Microsoft's research group, which specializes in basic research, and research applied to computer science and software engineering. This research group, one of the largest in the world in this field, includes 850 researchers in 10 laboratories throughout the world, including Israel. Harry Shum is the last in a long chain of Microsoft's senior officials that have arrived to Think Next events. Among these: Steve Ballmer, Ray Ozzie, Craig Monday, Chi Lo and Rick Rashid.

 

Besides Harry Shum, also appeared on the event stage a series of lecturers that break-thru in technological fields; among them: Doron Meirsdorf, Oshri Even Zohar and Eyal Shahar. James Whitaker, one of Microsoft's leaders in the technology field, also presented his views on this issue.

 

 Photos  Silvia Golan

 

 

President Peres met his Avatar on the Xbox One and visited the Ilumiroom which was presented for the first time in Israel

During the visit President Peres experimented with an application to explore space on an interactive table, met with young people who presented newly developed applications and met with employees of the company

The President of the State of Israel, Shimon Peres, visited Microsoft Israel earlier today (Tuesday) and during the visit he was presented with new technologies developed in Israel. President Peres was shown the new Microsoft entertainment console – Xbox One, which has been a great success across the world. While being shown the console, President Peres came face to face with his avatar, a surprise created for him by the employees of the company. Among the initiatives presented to President Peres was a kinetics camera which recognizes voice and movement and the new Microsoft development, Ilumiroom. The Ilumiroom projects expands and enriches the surroundings of the television set and changes the gaming and television watching experience. The Ilumiroom uses the kinetics camera to learn the lay out of the room and enhance the experience, the technology was shown in Israel for the first time.

 

During the rest of the visit President Peres experimented with the PixelSense table with touch technology which includes an interactive application to navigate through galaxies and stars. The application allows for study and research into space. Alongside the table President Peres was presented with technological applications developed by youngsters taking part in the Innovate for Good project.

 

President Peres congratulated the employees of Microsoft Israel during a meeting with them and said, "I am extremely proud of you and the work that you do. Greatness is to contribute to society and think in terms of generosity. I see you not only as an advanced technological company but a community organization based on technology. Israel's technological potential is vast. Within Israel we have talented people and we must find the ways to continue developments here."

President Peres was accompanied throughout the visit by the CEO of Microsoft Israel, Mr. Danny Yamin.

 

 

Photos Silvia G Golan

 

 

 

 

 

 

Israeli pride.  An innovative development with regards to babies' twisted feet. Children orthopedics is evolving with no need for casts or surgery.

UNFO MED Company was introduced this week during the thirty-third Orthopedics Conference held in Tel-Aviv. The company was previously titled one of Israel's promising companies in the Med in Israel Conference.  

 

What are the various ways of treating Metatarsus Adductus? Introducing a unique, easy-to- use solution, developed and manufactured in Israel, which solves the problem perfectly. 

Metatarsus Adductus is common amongst babies and is usually caused by the position of the baby in the womb. The baby's feet look like two halves moon bending towards one another. Up until today there has been no effective solution to this problem. The common treatment is the use of a special splint or casting of the foot till the baby turns 9 months old.

 

The cast is changed once a fortnight. The casts are outdated and were originally designated for a graver problem called Clubfoot. Usually the cast or splint is used till the baby starts walking. This obsolete and awkward treatment leads many families and doctors to avoid treatment due to the cumbersome process of changing the casts once a fortnight which is performed by a specialist doctor at a hospital or qualified stuff at a special ward. This tiresome process also requires preparation prior to the hospital visit. The process lasts for weeks and weeks and also involves dealing with hygienic issues related to the baby's stool and urine. When plastic casts are used the changing of casts is done by sawing which might cause injuries to the baby's feet.

 

In other cases, doctors recommend physiotherapy sessions at home, hoping to achieve some improvement. In such cases the responsibility falls on the parents rather than on the doctor. In the worst case scenarios, parents are sent home, being told that "there is no need for treatment, it will improve by itself". Indeed, sometimes the problem is solved without treatment, but in most cases it doesn't. One can never know in which case the problem will resolve itself and in which case the baby will continue to suffer from the problem and its side-effects in the future.

 

We are proud to introduce: a new, easy-to-use and effective solution to Metatarsus Adductus, made in Israel.

A one-of-a-kind biomechanical shoe which completely solves the problem. It is light, simple and elegant and has a unique feature – the shoe is worn below the ankle.

UNFO MED Ltd. which developed the footwear is an ISO 13485-certified orthopedic company.

The company was founded by Dr. Izak Daizade, a specialist in the field of orthopedic surgery with over 35 years of experience in the field. UNFO MED is the manufacturer of the revolutionary orthopedic system for newborn feet. The system is based on the expertise of Dr. Daizada in pediatric surgery. Dr. Daizade developed a treatment for Metatarsus Adductus and Clubfoot in newborns and is nowadays promoting this revolutionary treatment.

 

 

According to the company's owners there is no longer a reason to make do with answers such as "it will be fine" or "perhaps the problem will go away with time". You no longer have to go through the exhausting archaic treatments or complicated surgeries. The most important thing is to identify the problem at an early stage and start treating it with UNFO Foot Brace, preferably before the child is 6 months old. At a later stage it is much more difficult and complicated to treat the problem and it might even be impossible to do so.

 

What could happen if the child is not treated at all?   

According to Dr. Daizade it might cause future side effects which are usually reflected in footwear fitting, frequent wear and tear of shoes, calluses, pains, toes deformation and other orthopedic and aesthetic problems. It is easier to deal with the problem when the babies are younger and their skeleton is softer. You don't need to take the risk and see what the future holds.

Dr. Daizade adds that he is very proud that Israeli children are the first to enjoy this innovative treatment.

 

For further information :

Tel: 03-5010383

Address: 52 Weizmann Street, Holon

 

Photos provided by UNFO MED

 

 

 

      

Yair Shamir (Minister of Agriculture) and Todd Dollinger (Chairman and CEO of The Trendlines Group

On December 4, more than 250 professionals gathered at Eretz Yisrael Museum in Tel Aviv on Tuesday for an international conference exploring the state of agriculture technology and investment, specifically focusing on how Israel’s R&D advantage, the country’s unique multidisciplinary approach, and more than 100 years of experience tackling “food security” may indeed solve current global challenges. Distinguished panelists included members of the Israeli government, executives from leading international agrochemical and food companies, as well as venture capitalists from international agritech-focused firms.

 

Avi Hasson (Chief Scientist of the Israeli Ministry of Economy) and Steve Rhodes (Chairman and CEO of The Trendlines Group)

Margaret Dohnalek, global head of technology scouting in corporate R&D for PepsiCo, remarked that she understands “we don’t know what we need to know about Israel,” underscoring a sentiment across the panel of corporate executives, that technology currently being developed in Israel may be the next game-changer. The conference was part a 4-day Agrivest Tour of Israel organized by The Trendlines Group (www.trendlines.com), which included visits to Israel’s top agricultural research organizations, as well as agritech start-up success stories, such as Evogene and Bio-Bee.  

 

At the conference, Dohnalek, along with corporate leads from Syngenta, Bayer, and Monsanto spoke on a panel (“Profiling Tomorrow’s Ag Solutions”) offering insights into why companies are looking to Israel for the next addition to their pipelines, and discussed their “dream technologies.” Precision agriculture, with a focus on gaging weather patterns, was the most popular response.  Virginia Ursin, Technology Prospecting Lead at Monsanto added that this sector  -- “smart farming” -- is growing rapidly.

 

Ofra Strauss (Chairperson of the Board, Strauss Group) and Dr. Nitza Kardish (CEO of Trendlines Agtech)

 

Prof. Avi Perl, chief scientist, Israeli Ministry of Agriculture agreed and emphasized the formal funding structure the government gives to agritech start-ups as a sign of the government’s commitment to the sector’s growth and success. Dohnalek of PepsiCo said the formal support makes it more feasible for Israel entrepreneurs to successfully come up with ideas that address multiple challenges. She acknowledged this as a reason why large corporations seek collaborations and acquisitions in Israel. Ron Meeusen, managing partner of Cultivian Sandbox Ventures, said that what sets the Israeli start-up ecosystem apart is a culture of serial entrepreneurs who are willing to start over again and again.

Photos : Moshe Amar Liran Shemesh


"Through KKL-JNF, the Elkeles family continues to be a partner in the shaping of Israel's destiny, and once a trail is blazed, many people can walk on it."
KKL-JNF awarded the 2013 Samuel and Paula Elkeles Outstanding Scientist in Medicine Prize to Dr. Orly Elpeleg, the Head of the Department of Genetic and Metabolic diseases at Hadassah, at a moving ceremony at Hadassah Hospital in Jerusalem on Tuesday November 19. KKL-JNF World Chairman Efi Stenzler reaffirmed the organization's commitment to continue awarding this important prize in the future.
 


L-R: Barbara Goldstein, Harry Elyashiv, Prof. Orly Elpeleg, Efi Stenzler & Dr. Avigdor Kaplan. 
Photo: Tania Susskind

"I would like to congratulate Professor Orly Elpeleg, who was chosen as this year's recipient of the Samuel and Paula Elkeles Outstanding Scientist in Medicine Prize. Israel's entire populace and all of humanity benefits from your success," said KKL-JNF World ChairmanEfi Stenzler at the Elkeles prize giving ceremony at Hadassah Hospital in Jerusalem. The ceremony, which took place on Tuesday, November 19 was attended by Hadassah personnel, family, friends and distinguished guests, including Ms. Barbara Goldstein, a member of the KKL-JNF Directorate and the Deputy Executive Officer of Hadassah's office in Israel.


KKL-JNF World Chairman Efi Stenzler. Photo: Tania Susskind

"Israel is at the forefront of technological and scientific endeavor," Mr. Stenzler continued, "and many of KKL-JNF's achievements in various fields are based on innovative research, from desert afforestation, to recycling 87% of the country's wastewater for agriculture usage, and much more. Through KKL-JNF, the Elkeles family continues to be a partner in the shaping of Israel's destiny, and once a trail is blazed, many people can walk on it." 

Dr. Ludwig Elkeles established the foundation in memory of his parents, the late Samuel and Paula Elkeles. The family had its origins in Berlin, but Ludwig and his parents left Germany for England in 1936 as the Nazi regime rose to power. After the Second World War, Elkeles, an economist by profession, returned to Germany, and throughout the years maintained a strong connection with Israel. Towards the end of his life, he expressed a wish to donate his personal fortune to an enterprise that would benefit the Israeli public. He chose KKL-JNF as the partner for his donation, which was used to fund numerous projects, including a recreation area and playground in the Jerusalem Forest, a scenic lookout at Kadesh Barnea in the Negev, and the Mitzpe Gvulot site in the Negev. Elkeles also wished his estate to be used for the creation of a special foundation in memory of his parents, which would present an annual award for medical research.


Prof. Orly Elpeleg with Dr. Avigdor Kaplan. Photo: Tania Susskind

Towards the conclusion of the ceremony, Mr. Stenzler surprised the audience when he returned to the podium to make an exciting announcement: "The Elkeles prize has been awarded to outstanding scientists for the past twenty-five years, but at the present time, there are insufficient funds to continue this tradition. However, in recognition of the importance of encouraging medical research, KKL-JNF has decided to commit itself to continue awarding the prize in the future," Stenzler declared, to loud applause from the audience. 

This year's prize recipient is Dr. Orly Elpeleg, head of the Department of Genetic and Metabolic diseases at Hadassah. Over the past decade, she has focused on gene discovery in a large number of rare disorders, and has published reports on 30 novel disease-associated genes. She has participated in extensive national and international collaborations and has coauthored over 140 peer-reviewed articles. 

Dr. Avigdor Kaplan, Director General of Hadassah Medical Organization, said that seeing children suffer is what motivated Professor Elpeleg to try and discover the reason for their diseases. "Many of us saw the movie that described how a small girl who couldn't walk was eventually able to dance thanks to Professor Elpeleg's research. The entire Hadassah family is very proud of her." 

Professor Yaakov Naparstek, Head of the Division of Medicine at Hadassah, thanked KKL-JNF and the Elkeles family for awarding the prize. "It is my firm belief that biomedical research should be conducted at medical centers like Hadassah, where it is possible to go from the research bench to the patient's bedside, and vice-versa. There are those who think that doctors who are also research scientists are a dying breed, but at Hadassah Hospital, we feel that this is critical to the future of medical research. Dr. Elpeleg's success proves just how important this is."


Hadassah Elkeles, neice of Samuel Elkeles Z"L. Photo: Tania Susskind

Hadassah Elkeles, Samuel Elkeles' niece, who represented the family, said that this year's ceremony was especially moving for her, because the recipient of the prize is a woman. She spoke about her family's history, and mentioned that her family had donated to KKL-JNF during the 1920s, when they lived in Europe. "I even showed the receipts to Mr. Stenzler. My uncle, who had originally intended to study medicine, was a great supporter of Israel and KKL-JNF. In this family tradition, my father's last words were, 'Next year in the Land of Israel.'" 

Professor Orly Elpeleg was very moved to receive the prize. "Every successful research project needs partners, so I would describe this as our rather than as my research. In the 1980s, there were three categories of children's diseases – infectious diseases, cancerous diseases and all the rest, which were largely ignored in the textbooks, so I decided to research them. We were looking for disease-infected genes, which was sort of like looking for a specific carp in the ocean. To date, we have discovered 30 such genes, findings that have enabled breakthroughs in treating various children's diseases. 

"There is no research without belief – belief in your own personal ability, belief in your partners, and belief in your goal. I want to thank KKL-JNF and the Elkeles family, not for choosing me for the prize, but for highlighting our research. It is an affirmation of us and of our work." 

Dr. Osnat Levtziyon-Korach, Director of the Hadassah University Hospital on Mount Scopus, presented the committee's reasons for this year's choice, and the ceremony, which was graciously facilitated by KKL-JNF's Rivka Rey, concluded with the presentation of the prize and a KKL-JNF certificate of appreciation to Professor Elpeleg.